April 3, 2013

Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that two abstracts highlighting clinical and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for an oral presentation during a Clinical Trials symposium and a poster presentation at the American Association for Cancer Research (AACR) annual meeting, being held April 6-10, 2013, at the Walter E. Washington Convention Center in Washington, DC.

Details for the presentations are as follows:

Abstract:	LB-202
Title:	Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors
Date/Time:	Tuesday, Apr 09, 2013, 2:00 PM - 2:20 PM
Location:	Room 146
Session Title:	Clinical Pharmacology of Novel Agents in Solid Tumors (Clinical Trials Symposium)
Authors:	Geoffrey I. Shapiro, John Hilton, James M. Cleary, Sara M. Tolaney, Leena Ghandi, Eunice L. Kwak, Jeffrey W. Clark, Andrew Wolanski, Tracy Bell, John Schulz, Sheelagh Frame, Chiara Saladino, Morag Hogben, Scott J. Rodig, Judy H. Chiao, David Blake. Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital, Boston, MA, Cyclacel Ltd, Dundee, United Kingdom, Brigham and Women's Hospital, Boston, MA.

Abstract:	3418
Title:	Mechanism of cell death induced by the DNA strand-breaking nucleoside analogue CNDAC
Date/Time:	Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM
	Hall A-C, Poster Section 43, Poster Board Number: 13
Session Title:	Targeting Cell Cycle and DNA Damage
Authors:	Xiaojun Liu, Billie Nowak, Yingjun Jiang, Walter Hittelman, William Plunkett. UT MD Anderson Cancer Center, Houston, TX.

The abstracts can be accessed through the AACR website, www.aacr.org. Please note that according to AACR policy, all data are embargoed until the time of the beginning of the presentation.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company's most advanced oral product candidate, sapacitabine, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment of acute myeloid leukemia (AML) in the elderly and Phase 2 studies for AML, myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer. Cyclacel's pipeline includes seliciclib, a CDK inhibitor, in Phase 2 for lung and nasopharyngeal cancer and in Phase 1 in combination with sapacitabine; and CYC065, a second generation CDK inhibitor, in IND-directed development. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory

filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Contact for Cyclacel Pharmaceuticals, Inc.

Investors/Media: Corey Sohmer,

(908) 517-7330, csohmer@cyclacel.com